Abstract
BACKGROUND: Radiotherapy (RT) is a well-established treatment modality in multiple myeloma (MM), particularly for skeletal-related events. However, its role is likely evolving with the introduction of modern systemic treatments. METHODS: We conducted a retrospective analysis of a large, single-centre MM cohort treated with contemporary protocols to describe current patterns of RT use. RESULTS: RT continues to offer clinical benefit, with shifting patterns of use observed compared to historical cohorts. CONCLUSION: RT remains relevant in the modern MM landscape and may hold increasing value in later treatment stages. We postulate a future role as bridging therapy prior to CAR-T/bispecific antibody treatment. TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.